Citius Pharmaceuticals (NASDAQ:CTXR) Issues Earnings Results, Beats Expectations By $0.02 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) announced its quarterly earnings data on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02, Zacks reports. The firm had revenue of $1.49 million during the quarter, compared to the consensus estimate of $5.46 million.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR opened at $0.76 on Friday. The business’s fifty day moving average is $0.58 and its 200 day moving average is $0.69. The firm has a market cap of $20.74 million, a price-to-earnings ratio of -0.35 and a beta of 1.03. Citius Pharmaceuticals has a 52-week low of $0.47 and a 52-week high of $2.19.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Heights Capital Management Inc. bought a new stake in shares of Citius Pharmaceuticals during the fourth quarter valued at about $622,000. XTX Topco Ltd lifted its holdings in shares of Citius Pharmaceuticals by 572.8% in the fourth quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after buying an additional 91,196 shares in the last quarter. Asset Advisory Group Inc. bought a new position in shares of Citius Pharmaceuticals in the fourth quarter valued at approximately $46,000. Finally, NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals in the second quarter valued at approximately $40,000. Institutional investors own 16.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CTXR shares. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Zacks Research raised shares of Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.